Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 05/31/15
End: 11/30/22
Due: 11/30/23
Phase: N/A
Priority: Normal
Start: 11/30/10
End: 12/31/16
Due: 12/31/17
Phase: N/A
Priority: Normal
Start: 11/01/23
End: 12/31/25
Due: 12/31/26
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML | NCT02073838 | Sarit Assouline | user2@example.com | None | 2015-05-31 | 2022-11-30 | 2023-11-30 | - | - | 2025-07-14 |
| A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL) | NCT01238692 | Sarit Assouline | user2@example.com | None | 2010-11-30 | 2016-12-31 | 2017-12-31 | - | - | 2025-07-14 |
| Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML | NCT05413915 | Sarit Assouline | user2@example.com | None | 2023-11-01 | 2025-12-31 | 2026-12-31 | - | - | 2025-07-14 |